01—Abstract
Summary
Summary of the 8-K filed August 26, 2026. Cited figures are marked; the original filing is the authoritative source.
BeOne Medicines Ltd. (ONC) furnished this Form 8-K to disclose that it filed its 2026 Interim Report for the six months ended June 30, 2026 with the Shanghai Stock Exchange STAR Market.
The filing is primarily a regulatory disclosure under PRC rules, and it provides supplementary R&D expense data by product and project, prepared under U.S. GAAP. The Item 2.02 disclosure is furnished, not filed, and the STAR Interim Report itself is available only in Chinese on the SSE website. No headline revenue, net income, or guidance figures appear in the excerpt, so investors should treat it as a supplemental disclosure rather than a full earnings release.
The most quantitatively important data is R&D spending. Total R&D expense (U.S. GAAP) for the six months ended June 30, 2026 was $1,153.5 milliona, up about 14.6% from $1,006.8 million a year earlier. Internal R&D rose to $718.4 million from $606.5 million, while external R&D (including collaborations) rose to $435.1 million from $400.3 million.
Among key programs, BEQALZI (sonrotoclax) fell to $74.0 millionb from $94.0 million, and BRUKINSA fell to $42.7 million from $63.0 million, while newer programs such as BGB-43395 (CDK4), BGB-B2033, BG-C9074, BGB-58067 and BG-C477 more than tripled or grew sharply from small bases. Tacabrutideg (BTK-targeted CDAC) rose to $44.3 million from $26.9 million, signaling a shift in spending toward pipeline expansion. The filing also flags accounting differences between PRC GAAP and U.S. GAAP.
These cover share-based compensation attribution, interim tax rate methodology, lease expense presentation, and, most notably, the treatment of the 2025 sale of future royalty rights. Under U.S. GAAP the upfront proceeds are a liability with an effective-interest expense, while under PRC GAAP they are deferred revenue amortized over the collaboration period. These differences mean reported profit can differ materially between the two frameworks in any given period, so investors comparing STAR and SEC figures should reconcile them carefully.
02—Key points
Key Highlights
- Total U.S. GAAP R&D expense rose about 14.6% year over year to $1,153.5 million for the six months ended June 30, 2026, from $1,006.8 million.
- Internal R&D increased to $718.4 million from $606.5 million, a rise of roughly 18%, indicating growing in-house investment.
- Spending on several clinical programs grew sharply, including BGB-43395 (CDK4 inhibitor) to $22.7 million from $9.9 million and Tacabrutideg to $44.3 million from $26.9 million.
- BEQALZI (sonrotoclax) and BRUKINSA R&D spending declined to $74.0 million and $42.7 million, respectively, from $94.0 million and $63.0 million.
- External R&D and collaboration spending rose to $435.1 million from $400.3 million, with R&D collaboration projects up to $83.5 million from $47.6 million.
- The filing discloses material differences between PRC GAAP and U.S. GAAP, notably in accounting for the 2025 sale of future royalty rights (deferred revenue vs. liability with interest expense), which affect reported earnings comparability.
- The disclosure is furnished under Item 2.02 and not deemed filed under Section 18 of the Exchange Act; the full STAR Interim Report is only available in Chinese.
03—Questions
Frequently Asked Questions
Why did BeOne file this 8-K and what is the STAR Market report?
BeOne is listed on the Shanghai Stock Exchange STAR Market and must publish a half-year interim report under PRC securities rules. This 8-K furnishes supplementary information to U.S. investors, including R&D expense detail by product and a summary of PRC GAAP versus U.S. GAAP differences. The STAR report itself is in Chinese only.
How much did BeOne spend on R&D in the first half of 2026?
Total R&D expense under U.S. GAAP was $1,153.5 million for the six months ended June 30, 2026, compared with $1,006.8 million in the same period of 2025, an increase of about 14.6%. Internal R&D accounted for $718.4 million of that total.
Which programs are receiving more or less R&D investment?
Spending increased notably for Tacabrutideg, BGB-43395 (CDK4), BGB-B2033, BG-C9074, BGB-58067 and BG-C477, and for R&D collaboration projects. Spending decreased for BEQALZI (sonrotoclax) and BRUKINSA, and for other R&D projects, suggesting a shift toward newer pipeline assets.
Why could reported earnings differ between PRC GAAP and U.S. GAAP?
Key differences include share-based compensation expense recognition (accelerated vs. straight-line), interim tax rate methodology, lease accounting, and the treatment of the 2025 royalty sale. Under U.S. GAAP that upfront payment is a liability with interest expense, whereas under PRC GAAP it is deferred revenue recognized over the collaboration period, which can shift profit timing.
Does this filing include revenue, net income, or guidance?
The excerpt does not include revenue, net income, earnings per share, or guidance. Investors should consult the company's separate U.S. SEC quarterly or earnings materials for those figures.
04—Continue